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Abstract
Background Resistance to high-dose loop diuretics can be
overcome either by co-administration with thiazides or by
treatment with medium-dose loop diuretics combined with
thiazides. Combination therapy has been proven to be
superior to high-dose loop diuretic monotherapy for cardiac
and renal edema. However, such a strongly efficacious
short-term regimen is often complicated by undesired
effects, including circulatory collapse and electrolyte
disturbances. The question of whether the loop diuretic/
thiazide combinations are efficacious and safe when
conventional doses are combined has not yet been
answered.
Methods The effects of hydrochlorothiazide (HCT) and
torasemide (TO) given alone on the excretion of Na+, Cl-,
K+, Mg2+, and Ca2+ were compared with the effects of
combined administration of the diuretics in 12 healthy
volunteers.
Results The co-administration of HCT (25 mg) with TO (5
or 10 mg) strongly increased Na+ excretion. However, the
combination significantly reduced K+ and Mg2+ excretion.
The K+-sparing effect of the HCT/TO combination was
shown to be due to a significant reduction in the HCT-
induced increase in fractional K+ excretion by the loop
diuretic. Total excretion of Ca2+ relative to Na+ excretion
was less with the HCT/TO combination than with TO given
alone.
Conclusion The enhancement of desired NaCl excretion by
the HCT/TO combination with significant reduction of
undesired loss of K+ and Mg2+ meets clinical requirements
but has to be validated in long-term clinical trials.
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Introduction
High-dose monotherapy with loop diuretics has suc-
cessfully been replaced by the administration of
medium-dose loop diuretics combined with thiazides
in patients with chronic edema and chronic renal failure
[1–12]. Such combinations of diuretics, each acting on
different segments of the nephron—known as “sequen-
tial nephron blockade”—break the resistance to di-
uretics in edematous states [13–27]. Although this
physiologically grounded rationale is more effective
than high-dose monotherapy when a rapid and robust
diuretic response is needed, such treatment may lead to
complications such as fluid and electrolyte disturbances
[13, 28, 29].
Conventional-dose combinations of loop diuretics (e.g.,
5 or 10 mg torasemide) and thiazides (e.g., 25 mg
hydrochlorothiazide) have so far not been introduced in
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clinical practice for the long-term treatment of hypertension
or chronic heart failure. This is obviously due to the clinical
experience that high-dose loop/thiazide diuretic combina-
tions cause electrolyte disturbances.
In the present study, we examined conventional dose
combinations of loop diuretics and thiazides in healthy
volunteers free of any patient bias with particular focus on
the relationship between sodium, potassium, and magne-
sium excretion.
Methods
The ethically approved trial (University of Göttingen,
Germany) was performed on 12 healthy volunteers (28–
48 years old, 6 male, 6 female), who had given their
written informed consent to the study. Prior to adminis-
tration of a drug, they underwent a clinical check-up
including kidney, liver, and hematological tests, and
ECG. The participants were free of any medication.
They were kept on a standard diet, receiving a defined
fluid (1.5 l/day) and salt intake (100 mmole Na+ and 80
mmole K+ per day) 3 days before and throughout the
study. At least 1 week wash-out period was introduced
between series.
Diuretics used
As a representative thiazide, hydrochlorothiazide (HCT,
HEXAL Pharmaceuticals), 25 mg, was used in the study
since it has been available for long time and the greatest
body of evidence and experience has been accumulated for
it [30]. Torasemide (TO, HEXAL Pharmaceuticals), 5 or
10 mg, is a “newer” loop diuretic of the furosemide-type
with a longer duration of action and a significantly higher
bioavailability [31, 32]. The diuretics were given alone and
in combination. All diuretics were given orally in a single
dose under clinical control of the monitor of the trial.
Study protocol and analysis
In accordance with earlier studies [32, 33], urine was
collected after drug administration (8 A.M.) in the hospital
for a 24-h period, divided into two 3-h collections, one
6-h collection, and one 12-h collection. Baseline (control)
collections were obtained from 24 to 0 h prior to drug
administration using the same intervals (i.e., −24, −21, −18,
−12, 0 h). An aliquot of the defined volume of the
respective collection period was frozen until analyzed for
Na+, Cl−, K+, Mg2+, Ca2+, and creatinine using a
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Fig. 1 Effect of co-administered
loop diuretic torasemide (TO),
5 or 10 mg, with hydrochlorothi-
azide (HCT), 25 mg, on total
excretion of Na+ (upper panel)
and on the excretion of K+ and
Mg2+ (lower panel) as compared
to HCT alone. The left bar
presents the data for 0–12 h,
the right bar for 0–24 h
collection periods. The data are
means ± SE for 12 healthy
volunteers. For controls, further
excretion data, and statistical
analysis, see Table 1
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ing the glomerular filtration rate (GFR) and the fractional
excretion of K+, FEK, plasma creatinine, and plasma K
+
were taken prior to the study as well as 3, 6, 12, and 24 h
after drug administration. FEK represents the amount of K
+
excreted in the urine relative to the amount filtered (GFR ×
plasma K+).
First, total excretion of volume and electrolytes was
determined from urine collected in the respective periods.
Then net excretion induced by a diuretic regimen was
calculated for each participant from total excretion minus
baseline (control) obtained in the respective pretreatment
period. Thus, each run or experimental series was compared
with its own control 24 h prior to drug administration.
Statistical analysis
Administration of the diuretics alone and the diuretic
combination was performed in a randomized design. All
data are expressed as mean values ± SE. Statistical
evaluation was performed using analysis of variance
adjusted for multiple testing. Statistical significance was
accepted when P<0.05.
Results
Figure 1 illustrates total excretion rates of Na+, K+, and
Mg2+ obtained in 0- to 12-h and 0- to 24-h collection
periods. Hydrochlorothiazide (HCT, 25 mg) induced a
strong natriuresis for 12 h, consistent with the time of
action of this diuretic. The addition of the loop diuretic TO,
5 or 10 mg, to HCT strongly increased Na+ excretion in a
dose-dependent manner. With respect to a once-a-day drug
administration, which includes the postdiuretic period (12–
24 h), the co-administration of HCTwith TO increased total
Na+ excretion without being curtailed by postdiuretic Na+
retention.
Strikingly, K+ excretion did not increase in proportion to
Na+ excretion. Rather, K+ excretion declined with increas-
ing doses of TO co-administered with the thiazide. HCT-
induced excretion of Mg2+ was also reduced by increasing
doses of TO. These findings were then analyzed in detail by
a statistical evaluation of the excretion data given in
Table 1.
Compared to controls, HCT induced strong Na+ and Cl−
excretion. Positive NaCl excretion was maintained up to
24 h after drug administration. TO, however, induced
significant Na+ excretion only for 0–12 h. In terms of
mmoles, the HCT-induced excretion of K+ was about 40%
that of Na+. TO, however, was significantly less kaliuretic
than HCT. The loop diuretic did not increase K+ excretion
above control for the 0- to 12-h or 0- to 24-h periods.
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that of K+: HCT induced strong Mg2+ loss for 0–12 and
0–24 h as well, whereas TO did not significantly change
total Mg2+ excretion compared to controls.Concerning Ca2+
excretion, there was no Ca2+ loss during the 0- to 12-h and
0- to 24-h periods with HCT, whereas the loop diuretic
significantly increased Ca2+ excretion above control for the
0- to 12-h period only.
A comparison of combined administration of HCT and
TO versus HCT given alone shows that the combination is
a significantly stronger natriuretic regimen than HCT, both
for the 0- to 12-h and the 0- to 24-h period. Total excretion
of K+ relative to Na+ during 0–24 h was only 20% as
compared to 40% with HCT given alone. Also Mg2+
excretion was significantly reduced by the HCT/TO
combination as compared to HCT given alone. Ca2+
excretion obtained by the HCT/TO combination was greater
than that with HCT given alone only for 0–12 h. On the
other hand, a comparison of the HCT/TO combination with
TO given alone shows that total Ca2+ excretion induced by
the combination did not differ significantly from that
obtained with the loop diuretic given alone, although the
HCT/TO combination was by far a stronger natriuretic
regimen. Stated differently, total excretion of Ca2+ relative
to Na+ excretion with the HCT/TO combination equalled
that with HCT given alone, but was less than that obtained
by the loop diuretic given alone. Table 1 also includes the
HCT-induced transient fall in GFR (4–6 h after medica-
tion). This phenomenon was absent in the presence of TO,
in agreement with earlier reports [33].
Urinary excretion following drug administration is a
complex process as the drug effect is superimposed upon or
mixed with the baseline excretion of the kidney. Therefore,
we focused on the drug effect per se by calculating “net
excretion” rates free of the baseline excretion. Net excretion
was determined for each individual by taking into account
the baseline excretion in the respective pretreatment period
(see Table 1). The net natriuretic effect obtained by
combined administration of HCT (25 mg) and TO
(10 mg) was always significantly greater than the sum of
the net effects obtained by the components given alone.
This “supra-additive” natriuretic effect of the thiazide/loop
diuretic combination in healthy young volunteers exceeds
the sum of the individual effects by a factor of 1.3. It should
be noted (not given in Table 1) that the lower-dose
combinations of HCT (25 mg)/TO (5 mg) and HCT
(12.5 mg)/TO (5 mg) also resulted in a significant increase
in natriuresis of 30%. This phenomenon is in agreement
with earlier observations in edematous patients (see the
“Introduction” section).
In Fig. 2, the natriuretic net effects of HCT (25 mg) and
TO (10 mg) are plotted for the distinct collection periods.
The net effects of HCT and TO given separately are
combined in a single bar to be matched against the second
bar presenting the net natriuretic effect induced by
combined administration of HCT and TO. The time course
in Fig. 2 shows that the net diuretic effect of the loop
diuretic TO given alone was positive only for 6 h (periods
0–3 and 3–6 h). Throughout the remainder of the study
period (6–12 h, 12–24 h), net sodium excretion became
negative. After approximately 6 h, significant NaCl
retention occurred resulting in a “rebound effect” (Na+
excretion below baseline) that diminished the overall
natriuretic effect. In contrast, the thiazide diuretic acted
for approximately 12 h and lacked a significant rebound
effect. The rebound seen with TO given alone is effectively
reduced by co-administered HCT. Figure 2 illustrates that
combined administration of conventional doses of HCT and
TO is by far a stronger natriuretic regimen (“supra-
additive”) than when the components are given separately.
The diuretic-induced net excretion of K+ and Mg2+ is
illustrated in Fig. 3. After 12 h, combined administration of
25 mg HCT with 10 mg TO induced a net K+ excretion of
only about half the amount obtained by the individual
components given separately. The attenuation of HCT-
induced K+ loss by TO is also clearly demonstrated for the
0- to 24-h period: K+ loss following separate administration
of HCT and TO combined in the left bar was lowered to
about one-third by combined administration of HCT and
TO (right bar). The same effects held true for net Mg2+
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Fig. 2 Effect of HCT, 25 mg, and TO, 10 mg, and the combination
of both diuretics on “net excretion” of Na+. The data are plotted for
distinct collection periods to illustrate the time courses of the different
regimens. Net excretion was calculated as total excretion minus the
respective pretreatment baseline excretion in each individual for
each regimen. The effects of the components alone are combined
in the left bar to compare with the effect obtained by combined
administration in the right bar. Negative excretion (e.g., with TO
from 6–24 h) denotes less natriuresis than baseline excretion
(“rebound”). Effect of combined administration vs the sum of the
individual effects: *P<0.05
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It should be mentioned that the significant attenuation of K+
and Mg2+ excretion was also obtained by the lower dose
combinations of HCT and TO.
To focus on renal handling of potassium filtration and
excretion, the fractional K+ excretion was studied in the
presence of conventional doses of the thiazide and the loop
diuretic given alone and in combination. As illustrated in
Fig. 4, the FEK following the administration of 25 mg HCT
significantly increased during the 0- to 3-h period and most
evidently during the 3- to 6-h period to more than three
times baseline FEK of 0.1 on average. However, the loop
diuretic TO, 10 mg, did not significantly increase FEK
during these periods. Strikingly, the loop diuretic co-
administered with the thiazide significantly reduced the
HCT-induced increase in FEK during the time of action of
the thiazide, as also illustrated in Fig. 3. In the postdiuretic
period, the FEK of the HCT-containing regimen was still
slightly above baseline. Neither changes in blood chemistry
nor adverse drug reactions were observed throughout the
trial.
Discussion
The present experiments have shown that the co-
administration of conventional and lower doses of loop
and thiazide diuretics yielded a net diuretic/natriuretic effect
that was significantly greater than the sum of the net
individual effects of each class of diuretic. This finding is in
accordance with earlier observations first made in patients
with fluid retention (see the “Introduction” section). The
gain in natriuretic efficacy of about 30% in healthy young
volunteers needs further consideration. The addition of a
loop diuretic to a thiazide may enhance NaCl excretion by
several mechanisms, none of which are mutually exclusive.
Loop diuretics do not appear to potentiate the effect of a
thiazide by altering their pharmacokinetics or bioavailabil-
ity [29–31]. Rather, pharmacodynamic mechanisms seem to
play the predominant role in diuretic-induced electrolyte
excretion.
Given the axial organization of transport mechanisms in
the different segments of the nephron and the segment-
specific inhibition of salt transport by diuretics, the result of
treatment is the sum of all direct and indirect effects on
solute transport along the nephron. For example, when
NaCl reabsorption along the thick ascending limb of
Henle’s loop (TALH) is inhibited by loop diuretics, the













TO, 10 mg 
HCT + TO






0 – 12 h 0 – 24 h 
0 – 12 h 0 – 24 h 




Fig. 3 Effect of HCT, 25 mg, and TO, 10 mg, alone, and the
combination of both diuretics on net excretion of K+ (upper panel)
and Mg2+ (lower panel) plotted in paired bars (means ± SE). As in
Fig. 2, the effects of the diuretics HCT and TO given alone are
combined in the left bar to compare with combined administration in
the right bar. Data are cumulative for 0- to 12-h and 0- to 24-
h collection periods (see Table 1, data in parenthesis). Effect of
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Fig. 4 Effect of HCT, 25 mg, and TO, 10 mg, alone, and the
combination HCT/TO on fractional K+ excretion (K+ excreted
relative to K+ filtered) plotted for distinct collection periods. For
comparison, control FEK is also given. The results are means ± SE for
12 healthy volunteers. HCT or TO vs control: *P<0.05, HCT+TO vs
HCT: °P<0.05
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is greatly increased. In a microperfusion study in rats [34],
Na+ absorption rose by a factor of three under those
conditions. As a consequence, the apparent inhibition of
NaCl reabsorption in the loop of Henle is attenuated by
increased tubular reabsorption in more distal nephron sites.
This increase in sodium reabsorption can be blocked by
luminal thiazide acting on the early distal tubule. Hence, the
net effect of acute loop-diuretic administration on urinary
NaCl excretion reflects the sum of effects in the diuretic-
sensitive segment (e.g., inhibition of Na+/K+/2Cl− transport
in the TALH) and in the loop diuretic-insensitive segments
(secondary stimulation of NaCl reabsorption in the down-
stream distal tubule).
The combination of thiazides with loop diuretics prevents
not only the stimulating effect of luminal Na+ concentration
on NaCl uptake in the early distal tubule, but the thiazides
also inhibit carbonic anhydratase (CA) in the proximal
tubule, thereby increasing Na+ delivery to the TALH [24,
35–37]. This is due to the fact that thiazides retain a
sulfamyl side group on the benzene ring characteristic of a
CA inhibitor such as acetazolamide [36]. Thus, thiazides
play a dual role: they block the Na+/Cl− co-transport in the
early distal tubule and also—to varying extents—the proxi-
mal tubular CA. The order of potency for carbonic anhydratase
inhibition is chlorthalidone > benzthiazide > polythiazide >
chlorothiazide > bemetizide > hydrochlorothiazide > xipamide
[36].
In addition, loop diuretics also have a dual effect: first, they
block Na+/K+/Cl− transport in the TALH, and in addition,
they increase Ca2+ delivery to the distal tubule [36], which
decreases apical Na+ conductivity of the principal cells [38].
Thus, some further Na+ inhibitory effect—as is known to
occur with sodium channel blockers—contributes to the
supra-additive effect obtained with the combination HCT/TO.
Taken together, the HCT/TO combination inhibits NaCl
reabsorption at four sites of the nephron: in the proximal
tubule (HCT), in the loop of Henle (TO), in the early distal
tubule (HCT), and in the late distal tubule (TO). This mode
of action along the nephron corresponds to “sequential
nephron blockade.”
Thiazide monotherapy may—at least in short-term
treatment—be curtailed by a transient fall in GFR and a
consequent reduction in Na+ excretion [33]. Through the
co-administration of TO, known to block tubuloglomerular
feedback [32, 33], these effects could be prevented.
Postdiuretic NaCl retention (“rebound”) is known to be
more prominent the greater the peak natriuresis and the
shorter the duration of the diuretic’s action and is observed
with loop diuretics [39]. The net effect of a strong but short-
acting loop diuretic may therefore approach zero for a
24-h period. However, when combined with thiazides, the
natriuretic efficacy of loop diuretics can be improved and
maintained.
In long-term treatment with loop diuretics, “diuretic
adaptation” [40] develops associated with epithelial hyper-
trophy and hyperplasia, including the activation of Na+/K+-
ATPase [34, 41]. The administration of thiazides prevented
the activation of distal tubular Na+/K+-ATPase [42]. It was
also shown in humans [43] that chronic treatment with loop
diuretics enhanced ion transport in the distal tubule. These
data once again support the rationale for the combined
administration of loop diuretics with thiazides to counter-
balance the process of diuretic adaptation.
The finding of lowered excretion of K+ and Mg2+
despite the strong natriuretic efficacy of the HCT/TO
combination is novel and was unexpected. However, in a
previous microperfusion study in rats [35], it was shown
that thiazides such as HCT or tizolemide increase distal
tubular potassium secretion yielding a higher K+ excretion
than in controls. Yet these kaliuretic agents failed to
enhance distal potassium secretion when given together
with furosemide or piretanide. The inhibition of the
thiazide-induced increase in distal tubular K+ secretion
was left unexplained at that time.
Insights gained from more recent experiments now
permit a tentative explanation of the potassium-sparing
effect of low-dose diuretic combinations used in this trial.
Potassium is filtered by the glomeruli, and most of the
potassium filtered is reabsorbed from the lumen by the time
fluid emerges from the thick ascending limb of Henle’s
loop and enters the distal tubule. Potassium excreted in the
final urine (equal to approximately 10% of the amount
filtered) largely represents the amount secreted by the cells
of the connecting tubule and collecting duct. Potassium
secretion occurs through potassium channels, but this
process also depends on the presence of luminal membrane
sodium channels in the apical membrane of principal cells.
The co-existence of these two channels generates the
electrical driving force for potassium secretion [44]. Block-
ing sodium channels with K+-sparing diuretics such as
amiloride, for example, decreases the driving force for
potassium secretion in the distal tubule. Other agents also
have been shown to block the sodium channels of the distal
tubule [38]. For example, increases in luminal Ca2+
concentration in the range normally present in the distal
tubule reduce net K+ secretion by decreasing the electro-
chemical driving force for K+ secretion. These data may
be relevant to the present study and may help to explain
the potassium-sparing effects of combined HCT/TO
administration.
In rat microperfusion experiments [45], it was shown
that the ability of Na+ channel blockers such as amiloride to
inhibit distal tubular K+ secretion and Na+ reabsorption
requires the presence of luminal Ca2+. Since thiazides
stimulate Ca2+ reabsorption by the distal tubule [36] and
thus reduce the luminal Ca2+ concentration, thiazides alone
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might be expected to increase potassium excretion. Loop
diuretics, on the other hand, when co-administered with
thiazides might reduce K+ excretion by increasing distal
tubular Ca2+ concentration, inhibiting the sodium channel,
and decreasing the driving force for K+ secretion. Thus, the
loop diuretic/thiazide combination may show a stronger
antikaliuretic effect relative to Na+ excretion than the
antikaliuretic agent/thiazide combination. Therefore, TO
may have a dual effect in the nephron: it directly blocks the
Na+:K+:Cl− carrier in the TALH and, in addition, it could
affect distal tubular K+ secretion by increasing Ca2+
delivery as discussed above.
Given an equivalent natriuresis and diuresis, torasemide
was shown to be less kaliuretic than furosemide [46, 47].
This finding was attributed to an anti-aldosteronic effect of
torasemide, which was absent in furosemide [47, 48].
As shown recently, the regulation of collecting-duct
Na+/K+-ATPase and K+ excretion differs among loop
diuretics. Piretanide-treated rats increase bradykinin excre-
tion whereas furosemide-treated rats do not [49]. Bradyki-
nin production is considered to limit apical Na+ entry in
principal cells. Thus, Na+ reabsorption and K+ secretion by
the peritubular Na+/K+pump may not be activated. The
question of whether TO also produces bradykinin and thus
shows this additional mechanism to reduce K+ excretion
has not been investigated so far. There are, however, data
such as a positive volume and NaCl excretion 24 h after
dosing and a weaker kaliuretic effect of TO [32, 46, 47] that
agree with piretanide data [50] but differ from those of
furosemide [46, 47, 51].
The results obtained in this study address some
important clinical concerns. Thiazide-related metabolic
disturbances such as hypokalemia and hypomagnesemia
are dose-dependent. Since the goal of diuretic therapy is to
use the lowest possible diuretic dose to achieve adequate
effects, the results of this trial using conventional-dose
combinations meet this requirement. In previous studies,
reduction or prevention of thiazide-induced hypokalemia
and hypomagnesemia was attempted with the co-
administration of potassium-sparing diuretics such as
amiloride [52] or triamterene [53], yielding only additive
effects on net excretion of Na+, K+, and Mg2+ [54, 55].
However, the results from the present and previous studies
in rats suggest that in the presence of thiazides, potassium-
sparing agents such as amiloride will not be optimally
effective because luminal Ca2+ concentration is lowered by
the thiazide, and as discussed above, K+-sparing diuretics
require calcium to be most effective. The combination of
HCT with the loop diuretic TO, however, provides supra-
additive natriuretic effects associated with net K+- and
Mg2+-sparing effects. Nevertheless, these promising data of
our single-dose trial obtained in healthy volunteers have to
be validated in short- and long-term clinical trials.
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